2 Glioblastoma (GBM) is an aggressive incurable brain cancer. The cells that fuel 3 the growth of tumours resemble neural stem cells found in the developing and adult 4 mammalian forebrain. These are referred to as GBM stem cells (GSCs). Similar to 5 neural stem cells, GSCs exhibit a variety of phenotypic states: dormant, quiescent, 6 proliferative and differentiating. How environmental cues within the brain influence 7 these distinct states is not well understood. Laboratory models of GBM tumours can 8 be generated using either genetically engineered mouse models, or via intracranial 9 transplantation of cultured tumour initiating cells (mouse or human). Unfortunately, 10 these approaches are expensive, time-consuming, low-throughput and ill-suited for 11 monitoring of live cell behaviours. Here we explored whole adult brain coronal 12 organotypic slices as a complementary strategy to remove the experimental 13 bottleneck. Mouse adult brain slices remain viable in a neural stem cell serum-free 14 basal media for several weeks. GSCs can therefore be easily microinjected into 15 specific anatomical sites ex vivo. We demonstrated distinct responses of engrafted 16
Introduction 26
Glioblastoma multiforme (GBM) is a highly aggressive malignant brain tumour. 27
It is the most malignant form of glioma. Standard treatments involve combined 28 surgery, radiotherapy, and adjuvant temozolomide (TMZ) chemotherapy (Stupp et al., 29 2005) . However, long-term survival rates are extremely poor. Various obstacles 30 hamper development of effective therapies, including: pervasive tumour cell 31 infiltration, genetic heterogeneity (both intra-and inter-tumoural), therapeutic 32 resistance, blood-brain barrier, and lack of biological understanding of the disease. 33
Improved experimental models will help address some of these issues. 34 GBM tumour cells disseminate widely across many brain regions, often 35
following neuronal tracts and vasculature. Cells are therefore exposed to diverse 36 microenvironments, such as specific repertoires of cell matrix and growth factors, or 37 cellular niches (e.g. perivascular, invasive or hypoxic). These environmental cues 38 steer glioma stem cell (GSC) fate, affecting quiescence, proliferation, survival and 39 differentiation pathways (Codrici et al., 2016; Gilbertson and Rich, 2007) . Modelling 40 these various tumour cell-host brain interactions is therefore vital for improved 41 understanding of disease biology and development of new therapeutic strategies. 42
GSCs highjack many molecular programs that regulate neural stem cell self-43 renewal. Improved understanding of mechanisms controlling neural stem cell fate will 44 therefore likely lead to new insights into the disease and identification of critical 45 therapeutic targets. Neural stem cells (NSCs) are located within the lateral walls of the 46 forebrain ventricles in a region known as the subependymal zone (SEZ) (Doetsch et 47 al., 1999) . The SEZ provides a specific niche that sustains the NSCs throughout life. 48 NSCs are exposed to a myriad of cell-cell signals and ECM interactions that steer 49 NSC fate, such as: endothelial cells, ependymal cells, and cerebral spinal fluid 50 (Mirzadeh et al., 2008; Shen et al., 2008; Silva-Vargas et al., 2016) . Understanding 51 how tumour cells respond to normal SEZ is important, as this might serve as a 52 reservoir of tumour cells that underlie relapse in some patients (Piccirillo et al., 2015) . transplantation of freshly isolated or cultured GSCs into the adult rodent brain using 57 stereotaxic surgery is the 'gold standard' method to test tumour-initiating potential. 58 However, animal surgery and transplantation deep into the brain provides limited 59 experimental outputs: survival curves and end-point analysis of the resultant tumours. 60
Typically, these experiments take weeks or months and are non-trivial to setup. They 61 do not enable direct inspection of single cell behaviours such as invasion, monitoring 62 of quiescence and differentiation or responses to genetic or chemical perturbations. 63
These practical constraints have limited the scale and scope of studies aimed at 64 understanding and treating gliomas. To address this we explored the utility of 65 organotypic slice cultures to monitor GSC-host interactions. 66 Organotypic brain slice cultures were first developed in the 1960's (Crain, 67 1966). Since then they have been widely used by neuroscientists, particularly in 68 studies of neuronal function and circuits (reviewed in (Humpel, 2015)). Microdissected 69 regions are cultured above a semipermeable membrane in a cell culture insert and 70 exposed to serum-containing media from below. An example of their value are studies 71 using hippocampal slices cultures, widely deployed for studies of synaptic plasticity 72 and memory (Gahwiler et al., 1997) . Organotypic slice cultures overcome some of the 73 difficulties of in vivo studies as they provide ex vivo access to brain tissue architecture, 74 while still enabling direct observation and cell manipulations in the culture dish 75 (Humpel, 2015) . 76
In this study we demonstrate improved conditions enabling serum-free culture 77 of adult coronal whole brain slices in a manner that enables tracking of GSC 78 behaviors over several weeks. Our experimental approach provides a useful new 79 strategy to explore GBM. This model bridges the 'experimental gap' between in vitro 80 cell culture models and in vivo orthotopic transplantations. As an exemplar of the utility 81 of this approach we confirm engraftment of GSCs around blood vessels in the slice 82 culture and demonstrate how the method can be used in preclinical studies of 83 anticancer agents. 84
85

Results
86
Whole adult brain coronal slice cultures are viable for weeks in serum-free 87 neural stem cell media 88
Most studies employing organotypic slice cultures use postnatal mice and 89 dissect specific brain regions (e.g. hippocampus). However, GBM is predominantly a 90 disease of adults and cells disseminate across all brain regions. We therefore focused 91 on whole brain slices, reasoning that even short-term viability, for days or weeks, 92 could provide a useful model for testing tumour cell-host brain interactions. 93
Adult brains were harvested from young adult mice (~4 weeks) and the 94 olfactory bulbs and cerebellum were removed ( Figure 1A and B). We generated 95 whole-brain coronal sections using a vibratome to cut ~200um slices at the level of the 96 forebrain ventricle (6 slices per brain). Each section was placed on to a semi-97 permeable membrane culture insert and cultured in a six well cell culture plate ( Figure  98 1B). 99
Established organotypic brain slice protocols require high levels of serum or 100 growth factors. However, serum exposure will trigger astrocyte differentiation of NS 101 cells (Conti et al., 2005) ( Figure S1A -B). Culture media lacking serum or exogenous 102 growth factors was therefore tested. This reduces the risk of cell fate being primarily 103 directed by additives in the culture media, rather than endogenous tissue-derived 104 signals. Dying cells were identified at edges of the dissected region, using staining for 105 propidium iodide (PI). Serum-free NS cell-permissive culture media could indeed 106 support slices over several weeks ( Figure 1C ). By contrast, in basal media with no N2 107 or B27 supplements, tissues became necrotic in days ( Figure S1C ). 108
Within the healthy coronal sections, we were able to detect Dcx-expressing 109 neuroblasts, gliotubes and choroid plexus, suggesting the tissue retained key features 110 of a viable neurogenic niche ( Figure 1D ). In summary, whole brain coronal slices are 111 viable for several weeks in serum-free media -much longer than we anticipated -112 thereby providing an opportunity to assess responses of transplanted GSCs. 113 114
Patient-derived glioblastoma stem cells engraft into the mouse SEZ and retain 115 expression of quiescent NSC markers CD133 and CD9. 116
We next tested the potential of patient-derived human GSCs to engraft into the 117 slices. G7-GFP cells have previously been shown to be highly invasive when 118 transplanted into striatum of immunocompromised mice (Stricker et al., 2013 ). We first 119 tested microinjection of 10000 cells into the SEZ (Figure 2A ). One week later using 120 live cell imaging we noted large numbers of healthy GFP expressing cells successfully 121 engrafted. After 2 weeks slices were fixed and immunocytochemistry (ICC) confirmed 122 cells were viable and based on Ki67 and Stem121 expression ~10% were actively 123 proliferating ( Figure 2B ). We next assessed the known cancer stem cell marker 124 CD133 in the GFP cells after three weeks. Interestingly, CD133 expressing cells were 125 identified in a subset of cells, suggesting that GSCs generate phenotypic 126 heterogeneity in the slices and retain cells with cancer stem cell phenotype ( putative marker of qNSCs. Many of the G7 cells that were transplanted within the SEZ 132 expressed CD9 ( Figure 2D ). We conclude that human GSCs can engraft, survive and 133 proliferate in whole-brain slice co-cultures for at least 3 weeks, and can retain 134 expression of key cancer stem cell markers. 135 136
Patient-derived glioblastoma stem cells have distinct responses to region-137 specific adult brain microenvironments 138
We next compared how cells would respond in the SEZ versus other brain 139 regions in terms of their proliferation and differentiation. Four distinct regions were 140 tested: striatum, corpus callosum (CC), cortex and SEZ ( Figure 3A ). One week after 141 microinjection into a lateral region of the CC, we noted many G7 cells aligning with 142 and dispersing across the while matter tracts and displaying infiltrative morphology. These cells stably express GFP from a constitutive promoter. In vitro they express 159 GSC markers such as Nestin, Sox2, Olig2 ( Figure S2A ). IENS cells generate 160 aggressive infiltrative tumours when transplanted in vivo (n=4) ( Figure S2B ). These 161 were preferred to human patient-derived G7-GFP, as these displayed brighter GFP 162 and were less clumpy. 163 IENS cells were injected precisely into the SEZ through the wall of the lateral 164 ventricle. Initially, they displayed a remarkably specific localization and even 165 distribution throughout the SEZ (Supplementary Movie 1). Cells injected in parallel into 166 the striatum also survived and engrafted, but dispersed locally ( Figure S2C ). This may 167 suggest a preference, or homing, to the SEZ ( Figure 4A ), similar to previous reports 168 for normal NSCs (Kokovay et al., 2010). When imaged using confocal microscopy we 169 noted juxtaposition of GSCs with endothelial cells ( Figure 4C and Supplementary 170 movie 2). 5 days after microinjection the rate of proliferation was around 40-50% 171 (measured as Ki67 + cells of the GFP cells). ~15% began to express high levels of the 172 astrocytic marker GFAP ( Figure 4D ). Cells remained viable for two weeks and showed 173 evidence of proliferation and local infiltration into surrounding regions (n=3) ( Figure 4B Cellular responses were scored using immunocytochemistry for two markers: 188 gamma-H2AX for double strand breaks, and p53 as an indicator of DNA damage 189 response ( Figure 5A ). We first tested activity of each factor at previously reported 190 effective doses on IENS-GFP cultures in vitro, TMZ at 1,10 and 100µM and AraC at 1 191 and 2 µM ( Figure 5A-B) . We next treated slices harbouring successfully engrafted 192 IENS-GFP cells after 3 days with 100µM TMZ or 1µM Ara-C (24hr). Slices were then 193 assessed for Ki67 and pHH3 using immunocytochemistry ( Figure 5E test GSCs interactions with brain tissue. These methods therefore provide a tractable 212 ex vivo model system that can now be exploited in both basic and translational studies 213 of GBM. It is an approach that reduces the need for laborious and expensive mouse 214 breeding or stereotaxic surgery, thereby increasing the speed and experimental 215 throughput. 216
Avoiding exposure of transplanted cells to high levels of serum within the slice 217 cultures enables a more physiological signaling environment to be maintained. This 218 reduces the degree of serum-induced astrocyte differentiation which has hampered 219 our previous studies (unpublished observations). Although serum free media has been 220 used to maintain whole-mount tissue explants of the mouse SEZ for up to 16 hours 221 (Kokovay et al., 2010), to our knowledge longer term survival of whole coronal brain 222 slices in serum free media has not be reported for studies of GSCs. Surprisingly, we 223 found that serum wasn't needed in order to maintain healthy slices of the whole adult 224 coronal brain for many weeks. Slices seems viable in the basal neural media with no 225 exogenous growth factors and supplemented only with N2 and B27 hormonal 226
supplements. 227
With viable coronal adult brain slices we were able to assess the responses of proliferative responses were noted when cells were deposited at other anatomical 259 sites, such as corpus callosum. Distinct brain regions clearly will have significant 260 differences in their ability to influence tumour cell proliferation and differentiation and 261 this can now be further explored using this model. 262
A limitation of this technique might be the difficulties of achieving viable slice 263 cultures past 3 weeks. Although we did note some loss of some tissue integrity past 264 three weeks, we did not specifically assess later time points or search for modified 265 culture regimes. This might be important to resolve in future, particularly for slower 266 growing human GSCs, which take weeks to months to start initiate tumour growth in 267 live xenografted mice. 268 A multitude of new therapeutic agents are emerging that will require effective 269 preclinical studies before entering clinical trials for GBM. There is bottleneck and huge 270 cost associated with testing of new pharmacological agents in living animals. The 271 methods outlined here offer one potential solution. To demonstrate potential utility as 272 preclinical model, we tested the responses of cells to anti-mitotics (AraC and TMZ). 273 TMZ is used in many GBM patients, yet our understanding of how it influences distinct 274 compartments of the GSC and resistance mechanisms remains limited. Future 275 candidate drugs will need to be explored alongside TMZ to search for the most 276 effective doses and regimes. 277
In conclusion, the organotypic method presented here provides a simplified 278 model for assessing responses of GSCs to various brain anatomical sites and 279 microenvironments. This experimental model will therefore complement existing in 280 vitro and in vivo models, helping to prioritise genes and pathways controlling key 281 malignant properties of GBM and aiding the preclinical testing of new anti-cancer 282 agents. 283 284
Materials and Methods 285
Organotypic adult brain slice culture. 286 4-8 week-old C57BL/6 mice were used. More consistent results were often 287 obtained using the younger animals -particularly the viability after 2-3 weeks culture. 288
The brain was removed from the skull and transferred to a 10cm 2 tissue culture dish 289 with sterile PBS and placed on ice ( Figure 1A-1B ). Cerebellum and olfactory bulb were 290 removed ( Figure 1B) and remaining forebrain transferred into a 35mm 2 dish with pre-291 warmed 3% SeaPlaque™ agarose (50100 Lonza) ( Figure 1A-1B) . Upon cooling in ice 292 the block was removed and cut using a scapel into a ~ 2cm cube around the brain. 293
Prior to sectioning a 6-well plate was prepared: in each well we introduced one cell 294 culture insert (PICMORG50 Millicell) and added bellow it 1mL of culture media in 295 serum-free basal NS cell media, DMEM:F12 supplemented with N2 and B27 (Life 296 Technologies). The embedded brain was placed in the circular vibratome plate with 297 adhesive (Figure 1A-1B) . The vibratome (Leica VT1000 S) plate was fixed in the 298 platform and was filled with PBS with penicillin-streptomycin (Gibco 15140-122 1:100). 299 250 µm thick slices were cut, with vibrating frequency set to 8 and speed to 3. Each 300 slice was transferred using a small brush onto the top of a Millipore culture insert 301 ( Figure 1A-1B) . Six slices were cut per animal along the SEZ. The platform has to be 302 maintained cooled all the time. We obtained six slices around the forebrain ventricle. 303
The 6 well plate was placed in an incubator at 37ºC + 5% CO 2. Slices were incubated 304 for 1-2 days prior to cell transplantation. 305
Glioblastoma cancer stem cell transplantation onto brain slices 306
G7 human GBM stem cell cultures have been previously described (Stricker et 307 al., 2013) . For human cell transplants a standard Gilson pipette was used to deposit 308 0.2 ul of cells onto the centre of the striatum, the typical injection site when performing 309 stereotaxic surgery for tumour initiation assays. These cells engrafted well into the 310 slice and their integration could be observed the following day. 311 IENS-GFP mouse cells were a gift from Prof M. Lohuizen (Bruggeman et al., 2007) . 312
Both mouse and human GNS cells were grown using conditions previously described 313 (Pollard et al., 2009 ). After centrifugation cells were harvested and resuspended in 314 media at 100,000 cells/ul. Cells were used immediately for transplantation in the SEZ. 315
Two different methods of cells injection were used. A manual using a p2 Gilson pipette 316 was used to injected 0.5ul, while an auto-nanoliter injector (Nanoject II, Drummond 317 Scientific Company) was used for 40-100nl injections. For the injector we use glass 318 capillaries pulled using an automated needle puller (tip diameter, 10-20 μm; 319 Drummond) ( Figure 1B) . 4000 cells were transplanted per injection. 20000 cells were 320 transplanted when the P2 pipette was used. To facilitate engraftment and prevent 321 wide dispersion of the 0.2 ul of cells, we used forceps to make a small indentation in 322 the transplant site prior to delivery of the cells. Slices with cells were incubated at 323 37ºC + 5% CO 2 for 7 days, with fresh NS cell media (no EGF or FGF-2) added every 324 2 days. Cell engraftment was observed 4d after transplantation and cells could were 325 monitored using a fluorescence stereomicroscope (Leica M165 FC). For anti-mitotic 326 treatments in the IENS-GFP in vitro, different doses of the cytosine arabinoside (AraC) 327 (Sigma) were added to the complete media. For anti-mitotic treatments of IENS-GFP 328 in the slices, the cells were grown in the brain slice for 3 days and the AraC was 329 added to the complete media at different doses at 1uM and TMZ at 100uM for 24hr. 330 331 332
Immunocytochemistry 333
Media was removed and exchanged for 1mL of freshly prepare 4% paraformaldehyde 334 (PFA). 1-2 mL was also placed gently on top to cover the slice. After 2 hours PFA was 335 removed and brain slices were wash with PBS three times. Slices were transfer using 336 a brush to a 24 well plate. Slices were incubated at room temperature 1.5hr in 337 blocking solution (0.2% Triton X-100 and 3% Goat Serum; Sigma). Primary antibodies 338 GFAP (G3893 Sigma 1:100), Ki-67 (RM-9106 Thermo Fisher 1:100), GFP (13970 339
Abcam 1:100), CD31 (14-0311-81 eBiosience 1:100), CD9 (14-0091-82, eBioscience), 340 CD133 (MAB4310, Millipore), DCX (AB2253 Millipore), Nestin (1/10 Hybridoma Rat 341 401, DSHB), stem121(440410, Cellalartis), pHH3 (50-9124-41, eBioscience), H2AX 342 (phosphor S139) (ab81299, Abcam). 343
For H2AX staining cells were fixed in methanol-acetone 1:1 for 10min at room 344 temperature. Positive cells were scored using the Fiji image analysis software. For 345 IHC, the primary antibodies were incubated for 2d at 4ºC. After three washes with 346 PBS, slices were incubated with appropriate Alexa Fluor (Life technologies) secondary 347 antibody and DAPI (D9542-SIGMA) with for 4-6 hours. Slices were washed three 348 times and were mounting in a slide and immersed in FluoroSave TM Reagent (345789 349 Calbiochem). Slices were examined with a confocal microscope (Leica TCS SP8). 
